.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Rasagiline ratiopharm,...
After charting similar moves throughout 2024, Pfizer this week completed a sale ...
Purdue Pharma has submitted its latest opioid lawsuit settlement plan, including...
CEO Gina Chapman is also departing the company, which plans to review options fo...
Human medicines European public assessment report (EPAR): Fymskina, ustekinumab,...
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...
The campaign asks why people readily pick up their dogs’ poop while putting off ...
Mass General Brigham will invest $400 million to create a new cancer institute b...
A phase 3 trial of Immunovant’s FcRn inhibitor batoclimab has hit its primary en...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
A phase 3 trial of Immunovant’s FcRn inhibitor batoclimab has hit its primary en...
HHS is weighing plans to drastically cut U.S. government funding for domestic HI...
In the time since the Novartis gene therapy Zolgensma was approved for babies wi...
A pair of clinical data sets gives Novartis confidence in a new formulation of t...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
Health news stories you need to read today.
QRD statements for metered dose inhalers containing fluorinated greenhouse gases
The FDA has warned Aspen Pharmacare, the largest pharmaceutical company in Afric...
Black Diamond Therapeutics has found a partner for its deprioritized solid tumor...
The companies reported Wednesday that batoclimab showed improvements in myasthen...